Acute Myeloid Leukemia vs Acute Lymphoblastic Leukemia

Why Marrow crowding by proliferating myeloblasts suppressing normal hematopoiesis is correct

• In AML, acquired genetic/epigenetic lesions (e.g., FLT3, NPM1, CEBPA, IDH1/2) block myeloid differentiation while driving blast proliferation.
• The expanding clone of myeloblasts fills the marrow space (here 65% blasts) and suppresses normal erythroid, megakaryocytic, and granulocytic production, producing the triad of anemia, thrombocytopenia, and neutropenia.
• The needle-like inclusions are Auer rods, pathognomonic for AML and confirming a myeloid blast process.

Why the others are wrong

• Autoantibody-mediated peripheral destruction of mature circulating blood cells is the mechanism of autoimmune cytopenias (immune thrombocytopenia, autoimmune hemolytic anemia); it does not produce a marrow packed with 65% myeloblasts.
• Splenic sequestration of circulating mature erythrocytes and platelets occurs in hypersplenism, where peripheral pooling drives cytopenias but the marrow stays cellular with normal maturing lineages rather than blast-filled.
• Ineffective hematopoiesis with intramedullary apoptosis of mature precursors describes myelodysplastic syndrome or megaloblastic anemia, where a hypercellular marrow shows dysplastic but maturing precursors and fewer than 20% blasts, not 65% blasts with Auer rods.

Why Trisomy 21 gene dosage predisposing progenitors to leukemic transformation is correct

• This child's upslanting palpebral fissures, epicanthal folds, single transverse palmar crease, hypotonia, and repaired atrioventricular septal defect identify Down syndrome (trisomy 21); he has B-cell precursor acute lymphoblastic leukemia, and the dominant reason for his increased risk is trisomy 21.
• Trisomy 21 confers a roughly 10- to 20-fold increased risk of acute leukemia through gene-dosage effects (extra copies of chromosome 21 genes such as HMGN1 and DYRK1A that enhance B-cell progenitor proliferation) that predispose hematopoietic progenitors to leukemic transformation; childhood ALL also peaks at ages 2 to 5 years, matching this patient.

Why the others are wrong

• Latent Epstein-Barr virus infection immortalizing B-lymphocyte precursors — EBV immortalizes mature B cells and drives Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorder; it is not a cause of precursor B-cell ALL, and nothing in this vignette suggests EBV infection.
• Chronic antigenic stimulation driving clonal lymphoid expansion — chronic antigen drive underlies mature lymphoid neoplasms such as gastric MALT lymphoma (Helicobacter pylori) or hepatitis C-associated lymphoma, not the transformation of immature marrow lymphoblasts in a toddler.
• An inherited marrow-failure syndrome exhausting hematopoietic stem cells — syndromes such as Fanconi anemia raise leukemia risk, but this child's predisposition is explained by his trisomy 21, not a separate marrow-failure disorder, which is not described here.

Additional high-yield points

• Prior ionizing radiation is a genuine but secondary leukemogen; in a child with Down syndrome the constitutional trisomy 21 gene-dosage effect remains the dominant predisposition.